Business
Cosmo Announces Strategic R&D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett's Esophagus
Dublin, Ireland--(Newsfile Corp. - March 5, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced a strategic Research and Development Agreement with Amsterdam UMC and Eindhoven University of Technology to develop and clinically validate an artificial intelligence (AI)-based computer-aided detection (CADe) system for the identification of early neoplasia in Barrett’s esophagus. The collaboration represents an important step in expanding the clinical...
About this update from Cosmo Pharmaceuticals Nv
[{"type":"text","content":"Dublin, Ireland--(Newsfile Corp. - March 5, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced a strategic Research and Development Agreement with Amsterdam UMC and Eindhoven University of Technology to develop and clinically validate an artificial intelligence (AI)-based computer-aided detection (CADe) system for the identification of early neoplasia in Barrett’s esophagus. The collaboration represents an important step in expanding the clinical scope of Cosmo’s GI Genius™ platform beyond colorectal cancer screening into upper gastrointestinal (GI) indications.","length":601,"tagName":"p"},{"type":"text","content":"Barrett's oesophagus is a precancerous condition in which the pink, flat lining of the oesophagus (the tube that connects the mouth to the stomach) becomes damaged by acid reflux. This causes the lining to thicken and turn red. It affects millions of patients worldwide and increases the risk of esophageal adenocarcinoma, a type of cancer that starts in the esophagus. Detecting early neoplasia during upper GI endoscopy remains a significant clinical challenge, where AI-assisted tools may help physicians identify subtle abnormalities in real time.","length":555,"tagName":"p"},{"type":"text","content":"Over time, the program may support the development of additional AI applications within the GI Genius™ ecosystem, further expanding the platform’s clinical capabilities in upper gastrointestinal endoscopy.","length":205,"tagName":"p"},{"type":"text","content":"Through this collaboration, the parties will combine clinical expertise, imaging research capabilities and advanced engineering know how to curate high quality datasets, develop and train AI algorithms, and conduct structured clinical validation in specialized centers. The initiative is expected to generate one of the most comprehensive curated datasets for AI development in Barrett’s esophagus.","length":398,"tagName":"p"},{"type":"text","content":"Cosmo will lead the industrialization and regulatory pathway, ensuring the system is developed in accordance with applicable global quality, safety and cybersecurity standards and designed for seamless integration into the GI Genius™ platform. The program is intended to support future regulatory submissions in both Europe and the United States, subject to applicable approvals.","lengt...